U.S. Food & Drug Administration Approves Purdue Pharma Subsidiary’s Attention-Deficit/Hyperactivity Disorder Treatment

The U.S. Food and Drug Administration recently approved Adlon Therapeutics’ (Adlon) Adhansia XR, a drug treatment for attention-deficit/hyperactivity disorder (ADHD). Adlon Therapeutics—a subsidiary of Purdue Pharma—is a biopharmaceutical organization dedicated to developing and providing treatment options for ADHD and related disorders.

Adhansia XR is an extended-release capsule that stimulates the central nervous system for the treatment of ADHD in certain individuals ages 6 and older. Specifically, Adhansia XR is meant to increase attention and reduce restlessness in children and adults, helping them to concentrate for longer periods of time without becoming distracted or impulsive . . .